Valsartan in heart failure patients previously untreated with an ACE inhibitor

International Journal of Cardiology

Volumn 65, Issue 3, 1998, Pages 239-246

  Mazayev, V P ^a   Fomina, I G ^b   Kazakov, E N ^c   Sulimov, V A ^b   Zvereva, T V ^d   Lyusov, V A ^e   Orlov, V A ^f   Olbinskaya, L I ^b   Bolshakova, T D ^g   Sullivan, J ^h   Spormann, D O ^h  

^a NATIONAL MEDICAL RESEARCH CENTER FOR THERAPY AND PREVENTIVE MEDICINE   (Russian Federation)

^b Department of Internal Medicine ^*  (Russian Federation)

^c SHUMAKOV NATIONAL MEDICAL RESEARCH CENTER OF TRANSPLANTOLOGY AND ARTIFICIAL ORGANS   (Russian Federation)

^d NV Sklifosovsky Res Inst F   (Russian Federation)

^e Moscow Industrial University   (Russian Federation)

^f Inst for Adv Medical Training   (Russian Federation)

^g I M SECHENOV FIRST MOSCOW STATE MEDICAL UNIVERSITY   (Russian Federation)

^h NOVARTIS PHARMA AG   (Switzerland)

Author keywords

ACE inhibitor; Angiotensin II receptor antagonist; Angiotensin receptor blocker (ARB); Congestive heart failure; Lisinopril; RAS; Renin angiotensin system; Valsartan

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LISINOPRIL; VALSARTAN;

ADULT; AGED; ANGINA PECTORIS; ARTICLE; BLOOD PRESSURE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HEART OUTPUT; HEART RATE; HEMODYNAMICS; HUMAN; LUNG CAPILLARY PRESSURE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYSTEMIC VASCULAR RESISTANCE; VERTIGO;

ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEART FAILURE, CONGESTIVE; HEMODYNAMIC PROCESSES; HUMANS; LEAST-SQUARES ANALYSIS; LISINOPRIL; MALE; MATCHED-PAIR ANALYSIS; MIDDLE AGED; RECEPTORS, ANGIOTENSIN; RENIN-ANGIOTENSIN SYSTEM; TETRAZOLES; TIME FACTORS; VALINE;

EID: 0032146633     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0167-5273(98)00149-1     Document Type: Article

References (23)

1. [1] Sealey JE, Laragh JH. The renin-angiotensin-aldosterone system for normal regulation of blood pressure and sodium and potassium homeostasis. In: Brenner BM, Laragh JH, editors. Hypertension. New York: Raven Press, 1990:1287-1319.
2. [2] Hirsch AT, Dzau VT. Tissue renin-angiotensin systems: insights regarding the pathophysiology of heart failure. Heart Failure 1991;7:59-78.
3. [3] The CONSENSUS trial study group. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study. N Engl J Med 1987;3:1429-1435.
4. [4] Konstam MA, Rousseau MF, Kronenberg MW, et al. Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dysfunction in patients with heart failure. Circulation 1992;86:431-8.
5. [5] Demirel S, AkkayaV, Dinc C, et al. An open-label, uncontrolled trial of the angiotensin-converting enzyme inhibitor cilazapril in the treatment of patients with chronic congestive heart failure. Curr Therap Res 1997;58:594-600.
6. [6] Pacher R., Stanek B., Globits S. et al. Effects of two different enalapril dosages on clinical, haemodynamic and neurohumoral response of patients with severe congestive heart failure. Eur Heart J Aug 1996;17(8):1223-1232.
7. [7] Bellissant E, Annane D, Pussard E, et al. Systemic, pulmonary, brachial, renal and hepato-splanchnic hemodynamic effects of spirapril on severe congestive heart failure. Fundam Clin Pharmacol 1996;10(2):127-35.
8. [8] Mitrovic Y, Mudra H., Bonzel T., et al. Hemodynamic and hormonal effects of quinaprilat in patients with congestive heart failure. Clin Pharmacol Ther; June 1996;59(6):686-698.
9. [9] Giles TD. Comparison of lisinopril and captopril in the treatment of left ventricular congestive heart failure - influence of duration of action on efficacy and safety. Z Kardiol 1991;80(Suppl 2):35-9.
10. [10] The SOLVD investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325:293-302.
11. [11] Benedict CR, Weiner DH, Johnstone DE, et al. for the SOLVD investigators. Comparative neurohormonal responses in patients with preserved and impaired left ventricular ejection fraction: results of the Studies of Left Ventricular Dysfunction (SOLVID) registry. J Am Coil Cardiol 1993;22:146A-53A.
12. [12] Pitt B., ACE inhibitors in heart failure: prospects and limitations. Cardiovasc Drugs Ther 1997 May; 11(Suppl 1): 285-290.
13. [13] Blumenthal M. Treatment of congestive heart failure: experience with fosinopril. Am J Hypertens 1997;10(2):189S-98S.
14. [14] Lilly L, Dzau VJ, Williams GH, et al. Captopril vs hydralazine in advanced congestive heart failure: A multicenter study. Circulation 1985;72(Suppl 3):408.
15. [15] Swedberg K, Kjekshus J. Effect of enalapril on mortality on congestive heart failure. Follow-up survival data from the CONSENSUS trial. Drugs 1990;39(Suppl 4):49-52.
16. [16] Messerli FH, Weber MA, Brunner HR. Angiotensin II receptor inhibition. A new therapeutic principle. Arch Intern Med 1996 Sep 23; 156(17):1957-1965.
17. [17] Kang PM, Landau AJ, Eberhardt RT, Frishman WH. Angiotensin II receptor antagonists: a new approach to blockade of the reninangiotensin system. Am Heart J 1994;127:1388-401.
18. [18] Muller P, Cohen T, de Gasparo M, et al. Angiotensin II receptor blockade with single doses of valsartan in healthy, normotensive subjects. Eur J Clin Pharmacol 1994;47:231-45.
19. [19] Corea L, Cardoni O, Fogari R, et al. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: A comparative study of the efficacy and safety against amlodipine. Clin Pharm Ther 1996;60:341-6.
20. [20] Hoiwerda NJ, Fogari R, Angeli F, et al. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy and safety compared with placebo and enalapril. J Hypert 1996;14:1147-51.
21. [21] Hegner G, Faust G, Freytag F, et al. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy and safety compared with hydrochlorothiazide. Eur J Clin Fharmacol 1997;52:173-7.
22. [22] Crazier I, Ikram H, Awan N, et al. Losartan in heart failure -hemodynamic effects and tolerability. Circulation 1995;91:691-7.
23. [23] Baruch L. et al, in preparation.